Abstract
Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use
NU 2006-088
Invention
Linda J. Van Eldik
Heather A Behanna
Daniel Martin Watterson
Hantamalala Ralay Ranaivo
Short Description
Development of a new class of small molecule therapeutic candidates with potential to address areas of disease and injury relevant to tissue barrier dysfunction
Abstract
Northwestern researchers have discovered a new small-molecular inhibitor of myosin light-chain kinase (MLCK) as a potential therapeutic for treating sepsis and associated tissue injuries. They have identified Compound 6, which possesses the requisite molecular properties for bioavailability and demonstrates effective protection against endotoxin-induced vascular leakage and overall tissue injury and death. Compound 6 is a promising therapeutic candidate for acute lung injury and disorders involving tissue barrier dysfunction, including sepsis, lung injury, microvascular leakage, Crohn's disease as well as multi-organ failure.
Applications
Therapeutics: Small Molecule
Advantages
Bioavailability
Therapeutics for unmet area
Publications
Behanna HA, Watterson DM, Ranaivo HR (2006) Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: A lead compound that attenuates vascular leak. Biochimica et Biophysica Acta 1763: 1266-1274.
IP Status
Issued US Patent No. 7,732,445
Marketing Contact
Allan Nader, PhD
Invention Manager
(p) (847) 491-4456
(e) [email protected]
Original language | English |
---|---|
Patent number | 8791116 |
State | Published - Jan 31 2013 |